AU724212B2 - Down-regulation of DNA repair to enhance sensitivity to P53-mediated suppression - Google Patents

Down-regulation of DNA repair to enhance sensitivity to P53-mediated suppression Download PDF

Info

Publication number
AU724212B2
AU724212B2 AU36705/97A AU3670597A AU724212B2 AU 724212 B2 AU724212 B2 AU 724212B2 AU 36705/97 A AU36705/97 A AU 36705/97A AU 3670597 A AU3670597 A AU 3670597A AU 724212 B2 AU724212 B2 AU 724212B2
Authority
AU
Australia
Prior art keywords
dna
cell
cells
tumor cell
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU36705/97A
Other languages
English (en)
Other versions
AU3670597A (en
Inventor
Ruth A. Gjerset
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sidney Kimmel Cancer Center
Original Assignee
Sidney Kimmel Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sidney Kimmel Cancer Center filed Critical Sidney Kimmel Cancer Center
Publication of AU3670597A publication Critical patent/AU3670597A/en
Application granted granted Critical
Publication of AU724212B2 publication Critical patent/AU724212B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
AU36705/97A 1996-07-05 1997-07-02 Down-regulation of DNA repair to enhance sensitivity to P53-mediated suppression Ceased AU724212B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/675887 1996-07-05
US08/675,887 US6054467A (en) 1996-07-05 1996-07-05 Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
PCT/US1997/012542 WO1998001123A1 (en) 1996-07-05 1997-07-02 Down-regulation of dna repair to enhance sensitivity to p53-mediated suppression

Publications (2)

Publication Number Publication Date
AU3670597A AU3670597A (en) 1998-02-02
AU724212B2 true AU724212B2 (en) 2000-09-14

Family

ID=24712371

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36705/97A Ceased AU724212B2 (en) 1996-07-05 1997-07-02 Down-regulation of DNA repair to enhance sensitivity to P53-mediated suppression

Country Status (8)

Country Link
US (2) US6054467A (cg-RX-API-DMAC7.html)
EP (1) EP0910357B1 (cg-RX-API-DMAC7.html)
JP (1) JP2000516207A (cg-RX-API-DMAC7.html)
AT (1) ATE241973T1 (cg-RX-API-DMAC7.html)
AU (1) AU724212B2 (cg-RX-API-DMAC7.html)
CA (1) CA2259960C (cg-RX-API-DMAC7.html)
DE (1) DE69722621D1 (cg-RX-API-DMAC7.html)
WO (1) WO1998001123A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2729295A1 (fr) 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
US6573050B1 (en) 1999-10-29 2003-06-03 Sunnybrook & Women's College Health Sciences Centre Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma
AU2002230775A1 (en) * 2000-12-13 2002-06-24 Georgetown University Gene therapy for prostate cancer: sensibilization of cells to dn a damaging drugs and radiation
EP1348030B1 (en) * 2001-01-04 2009-11-25 Wadell, Göran Viral vector for gene therapy
US6586460B1 (en) 2001-04-02 2003-07-01 The Board Of Regents For Oklahoma State University Heteroarotinoids containing urea or thiourea linker
AU2002351241A1 (en) * 2001-12-04 2003-06-17 Nereus Pharmaceuticals, Inc. Methods and apparatus for cell based screening
US20050032728A1 (en) * 2002-12-17 2005-02-10 Sidney Kimmel Cancer Center Tumor suppression through bicistronic co-expression of p53 and p14ARF
WO2005012537A2 (en) * 2003-07-25 2005-02-10 Genvec, Inc. Adenoviral vector-based vaccines
US7649013B2 (en) * 2003-11-26 2010-01-19 Arqule, Inc. Methods of protecting against radiation injury
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
JP2008511336A (ja) * 2004-09-01 2008-04-17 アメリカ合衆国 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
CA2592699C (en) * 2004-12-31 2023-02-21 Per Sonne Holm Method for reversing multiple resistance in animal cells
JP2007119359A (ja) * 2005-10-25 2007-05-17 Fujifilm Corp 癌抑制剤
US20070280905A1 (en) * 2006-06-01 2007-12-06 Shulin Li Prognosis and Systemic Therapy for Treating Malignancy
KR101587687B1 (ko) * 2012-04-27 2016-01-21 가톨릭대학교 산학협력단 Ｓｒ11302 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
WO2017085351A1 (es) * 2015-11-20 2017-05-26 Servicio Andaluz De Salud Derivados del ácido retinoico para el tratamiento de la colestasis
US10722530B2 (en) * 2016-12-23 2020-07-28 Case Western Reserve University Methods of diagnosing and treating cancer
WO2019126816A1 (en) * 2017-12-22 2019-06-27 The Johns Hopkins University Regulation of mutant tert by braf v600e/map kinase pathway through fos/gabp in human cancer
WO2019207167A1 (en) 2018-04-27 2019-10-31 Fondazione Telethon Therapy of sulfatase deficiencies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532220A (en) * 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
ATE161039T1 (de) * 1988-10-31 1997-12-15 Univ California Erzeugnisse und verfahren zur regelung der suppression von neoplastischen phenotypen
US5527676A (en) * 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
IE911115A1 (en) * 1990-04-10 1991-10-23 Canji Inc Gene therapy for cell proliferative diseases
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
CA2152941C (en) * 1993-02-16 2003-04-22 Francis Mccormick Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2712602B1 (fr) * 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2712603B1 (fr) * 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2716893B1 (fr) * 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MI ETAL: PROC. AMER. ASSOC. CANCER RES. V 37, MAR 1996, P24 *
STIERUM ETAL: CARCINOGENISIS, V 16, NO.11, 1995, P2765 *
VENKATACHALAM ETAL: PRO.AMER.ASS.CAN.RES.V37, MAR'96,P137 *

Also Published As

Publication number Publication date
WO1998001123A1 (en) 1998-01-15
JP2000516207A (ja) 2000-12-05
EP0910357A1 (en) 1999-04-28
CA2259960C (en) 2008-04-29
US20050095226A1 (en) 2005-05-05
ATE241973T1 (de) 2003-06-15
DE69722621D1 (de) 2003-07-10
EP0910357B1 (en) 2003-06-04
AU3670597A (en) 1998-02-02
CA2259960A1 (en) 1998-01-15
US6054467A (en) 2000-04-25

Similar Documents

Publication Publication Date Title
AU724212B2 (en) Down-regulation of DNA repair to enhance sensitivity to P53-mediated suppression
AU723401B2 (en) 2-methoxyestradiol-induced apoptosis in cancer cells
EP0760675B1 (en) Compositions comprising dna damaging agents and p53
KR100688409B1 (ko) 신생물에 대한 종양 억제 유전자 요법 및 화학 요법의 조합치료 방법
KR19990071795A (ko) 암 진단 및 치료를 위한 방법과 조성물
AU724324B2 (en) p16 expression constructs and their application in cancer therapy
US20060052322A1 (en) Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
CA2277880A1 (en) Use of pea3 in tumor suppression
Chen et al. p53-insensitive PUMA down-regulation is essential in the early phase of liver regeneration after partial hepatectomy in mice
WO1998003195A1 (en) Methods and compositions for modulation of growth response
WO1998003195A9 (en) Methods and compositions for modulation of growth response
AU5001099A (en) Repression of cell transformation with human pea3
US20080293652A1 (en) Combination of Ad-P53 and Chemotherapy for the Treatment of Tumours
WO2000015648A1 (en) Adenoviral vector encoding pro-apoptotic bax gene and uses thereof
US20010010814A1 (en) Adenoviral vector encoding pro-apoptotic bax gene and uses thereof
HK1026579B (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)